文献速递肿瘤 PET/CT核素与放射性配体治疗

PRIMARY评分在前列腺临床显著癌检测中的诊断性能及与MRI相比的附加价值

The PRIMARY Score: Diagnostic Performance and Added Value Compared With MRI in Detecting Clinically Significant Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2023-11-29

这项回顾性队列研究纳入431例活检前同时接受68 Ga-PSMA PET/CT与MRI的男性,外部验证PRIMARY评分对临床显著前列腺癌(csPCa)的诊断性能及其对MRI分诊的附加价值。5级PRIMARY评分的AUC显著高于MRI(0.873 vs 0.786,P < 0.001),PRIMARY评分+MRI较单用MRI提高敏感度(96.0% vs 87.9%,P < 0.001)和阴性预测值(91.5% vs 79.1%,P < 0.001),避免24.6%(106/431)不必要活检,漏诊4.0%(9/223)csPCa。作者结论认为附加价值主要体现在MRI阴性或不确定(PI-RADS 1-3)的男性。

要点

  • 5级PRIMARY评分对csPCa的AUC为0.873,显著高于MRI的0.786(P < 0.001)。
  • PRIMARY评分+MRI较单用MRI提高敏感度(96.0% vs 87.9%)和阴性预测值(91.5% vs 79.1%),P均<0.001。
  • 联合策略避免24.6%(106/431)不必要活检,漏诊4.0%(9/223)csPCa。

核心结论

  • PRIMARY评分检测csPCa优于MRI,其附加诊断价值体现在MRI阴性或不确定结果的男性中。
  • PRIMARY评分+MRI较单用MRI提高csPCa的阴性预测值和敏感度。
  • 作者指出需进一步前瞻性试验验证临床怀疑csPCa但PRIMARY评分+MRI阴性者能否安全避免不必要活检。

研究设计与样本

  • 回顾性队列研究,纳入431例活检前同时接受68 Ga-PSMA PET/CT与MRI的男性。
  • 采用受试者工作特征曲线下面积和决策曲线分析评估诊断性能。
  • PRIMARY评分+MRI定义为PRIMARY评分3-5或PI-RADS 4/5任一阳性即为阳性。

主要发现

  • csPCa患病率为51.7%(223/431)。
  • 5级PRIMARY评分对csPCa的AUC为0.873,显著高于MRI的0.786(P < 0.001)。
  • 全组PRIMARY评分的敏感度90.6%、特异度61.1%、阳性预测值71.4%、阴性预测值85.8%,优于MRI PI-RADS的87.9%、49.0%、64.9%、79.1%。
  • PRIMARY评分+MRI较单用MRI提高敏感度(96.0% vs 87.9%,P < 0.001)和阴性预测值(91.5% vs 79.1%,P < 0.001),特异度和阳性预测值未受影响。
  • 联合策略避免24.6%(106/431)不必要活检,同时漏诊4.0%(9/223)csPCa。

关键数值与推荐

  • PRIMARY评分+MRI阳性定义为PRIMARY评分3-5或PI-RADS 4/5。
  • 5级PRIMARY评分对csPCa的AUC为0.873,MRI为0.786(P < 0.001)。
  • PRIMARY评分敏感度90.6%、特异度61.1%、阳性预测值71.4%、阴性预测值85.8%。
  • MRI PI-RADS敏感度87.9%、特异度49.0%、阳性预测值64.9%、阴性预测值79.1%。
  • PRIMARY评分+MRI敏感度96.0%、阴性预测值91.5%;单用MRI分别为87.9%、79.1%(P均<0.001)。

临床怎么用

  • 作者结论认为PRIMARY评分的附加诊断价值见于MRI阴性或不确定结果的男性。
  • 作者指出需进一步前瞻性试验验证临床怀疑csPCa但PRIMARY评分+MRI阴性者能否安全避免不必要活检。

局限性

  • 原文为回顾性队列研究。
  • 作者指出需进一步前瞻性试验验证临床怀疑csPCa但PRIMARY评分+MRI阴性者能否安全避免不必要活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiparametric MRI is the current standard for detecting clinically significant prostate cancer (csPCa). However, men with negative or equivocal MRI often undergo unnecessary biopsies due to concerns about false-negative results. The recently proposed 68 Ga-PSMA PET/CT-based PRIMARY score exhibited good diagnostic performance for csPCa. This study aimed to externally validate the performance of the PRIMARY score and evaluate its added diagnostic value to MRI triage in detecting csPCa. PATIENTS AND METHODS: This retrospective cohort study included 431 men who underwent both 68 Ga-PSMA PET/CT and MRI before biopsy. Performance was assessed using the area under the receiver operating characteristic curve and the decision curve analysis. The PRIMARY score + MRI was considered positive for either PRIMARY score 3-5 or Prostate Imaging Reporting and Data System (PI-RADS) 4/5. RESULTS: The prevalence of csPCa was 51.7% (223/431). The area under the receiver operating characteristic curve of the 5-level PRIMARY score for csPCa was significantly higher than that of MRI (0.873 vs 0.786, P < 0.001). For the entire group, sensitivity, specificity, positive predictive value, and negative predictive value of the PRIMARY score were 90.6%, 61.1%, 71.4%, and 85.8%, respectively, which outperformed 87.9%, 49.0%, 64.9%, and 79.1% of PI-RADS on MRI. The PRIAMRY score + MRI improved sensitivity (96.0% vs 87.9%, P < 0.001) and negative predictive value (91.5% vs 79.1%, P < 0.001) without compromising specificity and positive predictive value compared with MRI alone. This combined approach avoided 24.6% (106/431) of unnecessary biopsies, while missing 4.0% (9/223) of csPCa cases. The addition of the PRIMARY score in men with PI-RADS 1-3 showed a net benefit, but not in men with PI-RADS 4/5. CONCLUSIONS: The PRIMARY score was superior to MRI in detecting csPCa, and its added diagnostic value was in men with negative or equivocal MRI results. The PRIMARY score + MRI improved negative predictive value and sensitivity for csPCa compared with MRI alone. Further prospective trials will validate whether men with clinical suspicion of csPCa but negative PRIMARY score + MRI can safely avoid unnecessary biopsies.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Guo S, Kang F, Ma S, et al. The PRIMARY Score: Diagnostic Performance and Added Value Compared With MRI in Detecting Clinically Significant Prostate Cancer. Clin Nucl Med. 2023. PMID: 38081190. doi:10.1097/RLU.0000000000004951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。